
ACR Open Rheumatology

Vol. 4, No. 4, April 2022, pp 277–278 © 2021 The Authors. ACR Open Rheumatology published by Wiley Periodicals LLC on behalf of American College of Rheumatology. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.



DOI 10.1002/acr2.11397

Clinical Images: Severe proteinase 3 antineutrophil cytoplasmic antibody glomerulonephritis temporally associated with Sinovac Biotech's inactivated SARS-CoV-2 vaccine



Mass vaccination campaigns to prevent coronavirus disease 2019 (COVID-19) are occurring worldwide; not surprisingly, reports of rare postvaccination immune-mediated adverse events, as seen with the influenza vaccination (1), also started to surface, including cases of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) after receipt of the Pfizer-BioNTech and Moderna COVID-19 vaccines (2,3). Here, we report a case from Brazil of new-onset AAV temporally associated with inactivated COVID-19 vaccination. The patient, a previously asymptomatic 78-year-old White woman with a medical history of odontogenic maxillary sinusitis resolved after sinus surgery (in 2011), presented with asthenia, low-grade fever, and a mild dry cough 2 weeks after receiving Sinovac Biotech's COVID-19 vaccine (CoronaVac) on March 12, 2021 (second shot on April 5, 2021). Over the weeks, in addition to persistent fever, the patient experienced worsening of fatigue, weight loss, night sweats, and renal dysfunction. Of note, various antibiotics were empirically used until she underwent a kidney biopsy on June 22. At that time, she had leukocytosis, anemia, thrombocytosis, elevated inflammatory biomarkers and serum creatinine (peak at 7.3 vs 0.8 mg/dl on May 1, 2021), cytoplasmic ANCA 1:20 by indirect immunofluorescence (reference: negative), an anti-proteinase-3 level of 19 U/ml by fluorescent-enzyme immunoassay (positive >3 U/ml), a normal complement level, polyclonal hypergammaglobulinemia, and active urinary sediment. The diagnostic workup was negative for COVID-19 (reverse transcription-polymerase chain reaction), antinuclear antibodies (ANA), rheumatoid factor, cryoglobulins, anti-myeloperoxidase, anti-phospholipids, anti-Ro, anti-La, anti-Smith (Sm), anti-double-stranded DNA, anti-ribonucleoprotein (RNP), anti-glomerular basement membrane, HIV, and hepatitis B and C. Computed tomography (head, chest, paranasal sinuses, and abdomen), echocardiography, and nasal and laryngeal videoendoscopy findings were either normal or nonspecific. Urine and blood culture results were negative. The result of a kidney biopsy (14 glomeruli yielded) was compatible with necrotizing (9 of 14 glomeruli) and crescentic (cellular crescents in 6 of 14 glomeruli) glomerulonephritis. The renal biopsy specimen shows a cellular crescent and break of the glomerular basement membrane (periodic acid-Schiff stain, original magnification ×40) (A), break in Bowman's capsule (Jones stain, original magnification ×40) (B), an acute tubular injury (hematoxylin-eosin stain, original magnification ×40) (C), and fibrinoid necrosis in the glomerulus capillary loop

278 GARCIA ET AL

(hematoxylin–eosin stain, original magnification \times 40) (**D**). Renal immunostaining results were negative for C1q; C3; immunoglobulins A, M, and G; and light chains κ and λ . The patient received high-dose corticosteroids, pulse cyclophosphamide, and needed hemodialysis for 12 weeks. She is now controlled on low-dose corticosteroids and mycophenolate mofetil but with chronic renal impairment. To our knowledge, this is the first report of AAV possibly triggered by an inactivated COVID-19 vaccine.

Author disclosures are available at https://onlinelibrary.wiley.com/action/downloadSupplement?doi=10.1002%2Facr2.11397&file=acr211397-sup-0001-Disclosureform.pdf.

- Zafrir Y, Agmon-Levin N, Shoenfeld Y. Post-influenza vaccination vasculitides: a possible new entity. J Clin Rheumatol 2009;15: 269–70.
- Shakoor MT, Birkenbach MP, Lynch M. ANCA-associated vasculitis following Pfizer-BioNTech COVID-19 vaccine. Am J Kidney Dis 2021; 78:611–3
- Sekar A, Campbell R, Tabbara J, Rastogi P. ANCA glomerulonephritis after the Moderna COVID-19 vaccination. Kidney Int 2021;100: 473–4.

Diego Santos Garcia, MD
Cássio Martins, MD
Intensive Care Unit, Hospital Niterói D'Or
Niterói, Rio de Janeiro, Brazil
Elissa Oliveira da Fonseca, MD, PhD
Fonte Medicina Diagnóstica
Niterói, Rio de Janeiro, Brazil
Victor Côrtes Pourchet de Carvalho, MD, MSc
Rodrigo Poubel Vieira de Rezende, MD, MSc
Clinical Medicine Department, Universidade
Federal Fluminense
Niterói, Rio de Janeiro, Brazil